ClinicalTrials.gg
RecruitingNCT07672171Updated Jun 26, 2026

Far-Infrared Therapy for the Effect of Alzheimer Disease Dementia

An interventional study of Yin Fu Rui De Far-Infrared Radiator and Sham Far-Infrared Radiator in Dementia and Alzheimer Disease, sponsored by Juin-Hong Cherng. Recruiting at 1 site in Taiwan. Open to participants aged 61 Years to 92 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juin-Hong Cherng · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Oct 2022, registered Jun 2026).
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
61 Years to 92 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Alzheimer Disease with a site in Taiwan — 23 open to participants now, 27 under way, 8 of them phase 3. Alzheimer Disease · Taiwan.

Planned enrollment
69th of 90
40 · median 103
Started
2022
with 4 others
No phase
32 of 105
7 open now
Primary completion
2029-10
later than 20 of 26 live
Registered
102nd of 105
by date

Among the 105 studies in Alzheimer Disease with a site in Taiwan, this one is the 69th largest by planned enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2022, is one of 32 with no phase, reaches primary completion later than 20 of the 26 other live ones, and was the 102nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 105 studies in Alzheimer Disease with a site in Taiwan are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 61 Years to 92 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Alzheimer Disease with a site in Taiwan, or all of them as a file.
02

Study summary

Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder characterized by cognitive decline, including impaired learning ability, memory loss, and behavioral disturbances.

According to surveys conducted by the Ministry of Health and Welfare in Taiwan, the prevalence of dementia among individuals aged 65 years and older was estimated at 7.86% in 2018, affecting more than 280,000 individuals, and is projected to approach 900,000 by 2065, resulting in substantial medical, social, and economic burdens. Current pharmacological treatments provide only limited symptomatic benefits and may be associated with adverse effects. Therefore, safe and effective non-pharmacological interventions that may support cognitive function and reduce caregiver burden are urgently needed.

Experimental studies suggest that far-infrared (FIR) irradiation may enhance mitochondrial oxidative phosphorylation, increase ATP production, and promote microglial amyloid-β clearance, which may help delay the progression of Alzheimer's disease.

This trial aims to investigate the safety and effects of far-infrared (FIR) therapy on cognitive function in patients with Alzheimer's disease.

The findings may support the clinical application of FIR therapy as a non-pharmacological intervention to improve cognitive function and quality of life, reduce medication burden and treatment-related side effects, lessen caregiver burden, delay institutionalization, and reduce the social and economic burden associated with Alzheimer's disease.

Read the detailed description

Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, behavioral disturbances, and deterioration in activities of daily living. According to surveys conducted by the Ministry of Health and Welfare in Taiwan, the prevalence of dementia among individuals aged 65 years and older was estimated at 7.86% in 2018, affecting more than 280,000 individuals, and is projected to approach 900,000 by 2065. As the disease progresses, increasing cognitive impairment places substantial medical, social, and economic burdens on patients, caregivers, and healthcare systems. Current pharmacological treatments for Alzheimer's disease provide limited symptomatic benefits and may be associated with adverse effects. Therefore, alternative non-pharmacological interventions that may support cognitive function and improve quality of life are being actively explored.

Experimental studies have suggested that far-infrared (FIR) irradiation may exert beneficial biological effects on mitochondrial function and neuroinflammation. FIR exposure has been reported to enhance mitochondrial oxidative phosphorylation, increase adenosine triphosphate (ATP) production, and improve microglial activity involved in amyloid-β (Aβ) clearance. These mechanisms may potentially delay neurodegeneration associated with Alzheimer's disease progression.

This clinical study is designed as a single-center, randomized, single-blind, parallel-group controlled trial conducted in Taiwan. A total of up to 40 participants with Alzheimer's disease will be enrolled and randomly assigned in a 1:1 ratio to either the active FIR treatment group or the sham-control group. The investigational device is the Yin FuRui De Far-Infrared Therapy Device (Model CE-1889), which generates far-infrared wavelengths ranging from 4 to 14 μm.

Participants in the treatment group will receive daily FIR irradiation therapy using a head-mounted FIR device. FIR irradiation will be applied once daily to the Fengfu (GV16) and Baihui (GV20) acupoints for 30 minutes per site. Participants in the control group will use an identical device with the FIR function disabled. Prior to home use, study personnel will provide device-use training and instructions to participants and their caregivers.

The primary objective of the study is to evaluate the safety of the FIR therapy device. Safety assessments will include monitoring the incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) associated with the investigational device throughout the study period.

Secondary objectives include evaluating changes in cognitive performance using the Mini-Mental State Examination (MMSE) and assessing mitochondrial function biomarkers obtained from peripheral blood samples. Outcome assessments will be conducted at baseline, Month 1, Month 3, and Month 12.

Safety analyses will be conducted in the Intent-to-Treat (ITT) population. Baseline normal and post-treatment abnormal cases, as well as their proportions, will be summarized separately for the intervention and control groups. The number and incidence rate of adverse events (AEs) and serious adverse events (SAEs) will be calculated and descriptively analyzed. Group comparisons of adverse event incidence will be performed using the Chi-Squared test. Efficacy analyses for MMSE scores and mitochondrial function biomarkers will include paired-sample t tests and independent-sample t tests, as appropriate.

This study aims to determine whether the head-mounted FIR therapy may serve as a safe adjunctive non-pharmacological intervention for patients with Alzheimer's disease to support cognitive function, improve quality of life, reduce caregiver burden, and potentially delay disease progression and institutional care.

03

Conditions studied

  • Dementia
  • Alzheimer Disease

Browse trials for

Keywords

  • Far-infrared therapy
  • Dementia
  • Alzheimer disease
04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Juin-Hong Cherng is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
61 Years to 92 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with Alzheimer's disease dementia.
  2. (MMSE) score between 18 and 24 (inclusive).
  3. Currently prescribed and maintained on a stable regimen of anti-dementia medication.
  4. No sensory deficits or impairment regarding skin temperature perception.
  5. Patient or a Legally Authorized Representative (LAR) must be willing and capable of providing written prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Non-Alzheimer's disease dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia).
  2. Known to heat or light, including the current use of photosensitizing medications.
  3. Diminished thermal or heat sensitivity, such as from the concurrent use of analgesics, sedatives, or consumption of alcoholic beverages.
  4. Acute injury or acute localized inflammation, including active inflammation, infection, or ulcerated wounds.
  5. Concomitant acute venous thrombosis, varicose veins, severe peripheral arterial occlusive disease (Stage III or IV), lymphatic disease, acute rheumatoid arthritis, acute gout, or active fever.
  6. Presence of mottled erythema or other abnormal dermatological conditions on the scalp or neck.
  7. Localized skin lesions, damage, or open wounds at the device contact sites.
  8. Concurrent participation in any other clinical trial.
  9. Any other underlying pathological conditions or clinical statuses that, based on medical consensus, would preclude safe participation in the study.
  10. Failure or refusal to provide signed .
  11. Inability or unwillingness to comply with the trial protocols, schedules, or required follow-up evaluations.
  12. History or presence of hemorrhagic disorders or bleeding-related diseases.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active Far-Infrared (FIR) Therapy

    Participants will receive active far-infrared (FIR) therapy using a head-mounted FIR device (Yin Fu Rui De Far-Infrared Therapy Device, Model CE-1889). The device delivers far-infrared irradiation (4-14 μm) and is applied to Fengfu (GV16) and Baihui (GV20) acupoints for 30 minutes per site, once daily for 12 months. The intervention will be initiated under supervised training at the study site, followed by home-based self-administration by participants and/or caregivers. Participants will continue their usual medical care without changes to standard pharmacological treatment.

    Device: Yin Fu Rui De Far-Infrared Radiator

  • Sham comparator
    Sham Control

    Participants will receive a sham intervention using an identical-appearing head-mounted device (Yin FuRui De Far-Infrared Therapy Device, Model CE-1889) with the far-infrared emission function disabled. The sham device will be applied to the same acupoints (Fengfu GV16 and Baihui GV20) for 30 minutes per site, once daily for 12 months. Procedures, duration, and application schedule will be identical to the active treatment group to ensure blinding. The sham device does not emit far-infrared radiation.

    Device: Sham Far-Infrared Radiator

Interventions

  • DeviceYin Fu Rui De Far-Infrared Radiator

    The investigational device is a head-mounted far-infrared therapy device manufactured in Taiwan. * Emission wavelength: 4-14 μm * Heating mechanism: ceramic semiconductor heating element * Design: head-mounted structure with external housing to reduce energy dissipation * Application sites: Fengfu (GV16) and Baihui (GV20) Regulatory status: Approved medical device (Medical Device License No. 006083 issued by the Taiwan Food and Drug Administration (TFDA), Ministry of Health and Welfare, Taiwan). Approved indications include relief of fatigue, improvement of local blood circulation, and reduction of muscle stiffness and neuralgia. In this study, the device is used investigationally to evaluate potential effects on cognitive function in patients with Alzheimer's disease dementia.

    Also known as: Yin Fu Rui De Far-Infrared Radiator (Model CE-1899)

  • DeviceSham Far-Infrared Radiator

    The sham device is identical in appearance to the active device but without active far-infrared emission. It is used to maintain participant blinding and control for non-specific effects in device-based interventions.

    Also known as: Sham Far-Infrared Device (Model CE-1889)

07

What researchers measure

Primary outcomes

  1. Number of Participants With Yin Fu Rui De Far-Infrared Therapy Device-Related Adverse Events (AEs)

    Safety will be evaluated by tracking any unfavorable clinical occurrence associated with the use of the Yin Fu Rui De far-infrared therapy device, assessed through regular clinical physical examinations and documented via Case Report Forms (CRFs). The unit of measure is the number of participants experiencing at least one AE. Safety analysis will be performed using the Intent-to-Treat (ITT) population (N=40). Following the protocol's statistical plan, the specific clinical manifestations, severity, and device-causality of all AEs will be documented. The proportions of pre-treatment normal versus post-treatment abnormal cases, along with AE incidence rates, will be calculated and compared between the intervention and control groups using the Chi-Squared Test. Unit of Measure: Number of participants

    Time frame: Baseline (Day 1), Month 1, Month 3, and Month 12 for each participant.

  2. Number of Participants With Yin Fu Rui De Far-Infrared Therapy Device-Related Serious Adverse Events (SAEs)

    Safety will be evaluated by focusing on serious safety concerns associated with the use of the Yin Fu Rui De far-infrared therapy device, assessed through clinical evaluations and documented via Case Report Forms (CRFs). Serious adverse events (SAEs) are defined as events resulting in death, life-threatening conditions, prolonged hospitalization, or permanent disability. Safety analysis will be performed using the Intent-to-Treat (ITT) population (N=40). The relationship between the device and SAEs will be documented, and the proportions of pre-treatment normal versus post-treatment abnormal cases, alongside SAE incidence rates, will be statistically compared between the intervention and control groups using the Chi-Squared Test.

    Time frame: Time Frame: Baseline (Day 1), Month 1, Month 3, and Month 12 for each participant.

Secondary outcomes

  1. Change From Baseline in Cognitive Function Score Assessed by MMSE

    Assessment of cognitive improvement or decline using the Mini-Mental State Examination (MMSE), a standardized 30-point questionnaire. Following the protocol's statistical plan, within-group changes from baseline will be analyzed using paired-sample t-tests, and differences in changes between the intervention and control groups will be compared using independent-sample t-tests. Unit of Measure: Score on the MMSE scale (Range: 0 to 30, where higher scores indicate better cognitive function)

    Time frame: Baseline (Day 1), Month 1, Month 3, and Month 12 for each participant.

  2. Change From Baseline in Mitochondrial Adenosine Triphosphate (ATP) Production Rate

    Evaluation of mitochondrial energetic pathways and cellular respiration efficiency through peripheral blood biomarker analysis. This test involves collecting blood samples (totaling less than 20 mL) to measure the quantitative rate of mitochondrial ATP production using a standardized fluorometric assay. Following the protocol's statistical plan, within-group changes from baseline will be analyzed using paired-sample t-tests, and differences between the intervention and control groups will be evaluated using independent-sample t-tests. Unit of Measure: picomoles per minute per milligram of protein (pmol/min/mg)

    Time frame: Baseline (Day 1), Month 1, Month 3, and Month 12 for each participant.

08

Study locations

1 of 1 sites recruiting
  • Trial-Service General Hospital, National Defense Medical University
    Taipei, 11490, Taiwan
    Recruiting
    • Juin-Hong Cherng, Ph.D. · Contacti72bbb@gmail.com · 886-2-87923100
    • Gang-Yi Fan, Ph.D. · Contactu9310318@gmail.com · 886-2-87923100
    • Jiunn-Tay Lee, M.D. · Principal investigator
    • Chia-Lin Tsai, Ph.D. · Sub investigator
    • Chia-Kuang Tsai, Ph.D. · Sub investigator
09

References and documents

Publications

  • Leong, K.-I., Chen, Y.-C., & Chen, J.-H. (2014). Dementia: A focused review. Journal of Internal Medicine of Taiwan, 25(3), 151-157. https://www.mohw.gov.tw/dl-77702-2060aef3-99b0-48b0-97ff-53d1210b6acf.html
  • Chen H, Chen F, Jiang Y, Zhang L, Hu G, Sun F, Zhang M, Ji Y, Chen Y, Che G, Zhou X, Zhang Y. A Review of ApoE4 Interference Targeting Mitophagy Molecular Pathways for Alzheimer's Disease. Front Aging Neurosci. 2022 May 20;14:881239. doi: 10.3389/fnagi.2022.881239. eCollection 2022. PubMed 35669462 ↗
  • Hsieh, Y.-Y., Lin, J.-P., Liu, W.-C., & Lin, C.-C. (2007). Medical applications and the action mechanisms of far-infrared ray. Taiwan Journal of Applied Radiation and Isotopes, 3(3), 333-340. https://doi.org/10.29832/TJARI.200709.0002
  • Department of Statistics, Ministry of Health and Welfare (September 18, 2020). World Alzheimer's Day Health and Welfare Statistics Bulletin, Department of Statistics, Ministry of Health and Welfare. https://dep.mohw.gov.tw/DOS/cp-5112-63351-113.html
  • Vatansever F, Hamblin MR. Far infrared radiation (FIR): its biological effects and medical applications. Photonics Lasers Med. 2012 Nov 1;4:255-266. doi: 10.1515/plm-2012-0034. PubMed 23833705 ↗
  • Li Q, Peng J, Luo Y, Zhou J, Li T, Cao L, Peng S, Zuo Z, Wang Z. Far infrared light irradiation enhances Abeta clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer's disease-like mice. J Neuroinflammation. 2022 Jun 14;19(1):145. doi: 10.1186/s12974-022-02521-y. PubMed 35701825 ↗
  • Huang PH, Chen JW, Lin CP, Chen YH, Wang CH, Leu HB, Lin SJ. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions. Cardiovasc Diabetol. 2012 Aug 15;11:99. doi: 10.1186/1475-2840-11-99. PubMed 22894755 ↗
  • Fukui K, Kimura S, Kato Y, Kohno M. Effects of far infrared light on Alzheimer's disease-transgenic mice. PLoS One. 2021 Jun 17;16(6):e0253320. doi: 10.1371/journal.pone.0253320. eCollection 2021. PubMed 34138944 ↗
  • Fairley LH, Wong JH, Barron AM. Mitochondrial Regulation of Microglial Immunometabolism in Alzheimer's Disease. Front Immunol. 2021 Feb 25;12:624538. doi: 10.3389/fimmu.2021.624538. eCollection 2021. PubMed 33717134 ↗
  • Chen TY, Yang YC, Sha YN, Chou JR, Liu BS. Far-Infrared Therapy Promotes Nerve Repair following End-to-End Neurorrhaphy in Rat Models of Sciatic Nerve Injury. Evid Based Complement Alternat Med. 2015;2015:207245. doi: 10.1155/2015/207245. Epub 2015 Feb 3. PubMed 25722734 ↗

Related links

Individual participant data

Plan to share: No — To protect the privacy and confidentiality of the participants in accordance with personal data protection regulations, individual participant data (IPD) will not be publicly shared. The clinical study results will be disseminated exclusively through aggregated data in peer-reviewed scientific publications and official trial registries.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2029, 84 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 84 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 26, 2026
StartActual
Oct 15, 2022
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 31, 2029
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07672171
Lead sponsor
Juin-Hong Cherng
Collaborators
Tri-Service General Hospital (TSGH)
Responsible party
Juin-Hong Cherng (Associate Professor, National Defense Medical Center, Taiwan) — Sponsor-investigator
First posted
Jun 26, 2026
Start date
Oct 15, 2022
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Jun 26, 2026

Study contacts

Juin-Hong Cherng, Ph.D.
Contact
i72bbb@gmail.com
886-2-87923100 ext. 18681, 18699
Gang-Yi Fan, Ph.D.
Contact
u9310318@gmail.com
886-2-8792-3100 ext. 18699
Jiunn-Tay Lee, M.D.
principal investigator · Trial-Service General Hospital, National Defense Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion